| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $4,426,494 | 2 | 4 |
Sells | $4,860,444 | 55 | 96 |
| Manning Paul B | director | 1 | $3M | 0 | $0 | $3M |
| Caligan Partners LP | See Remarks | 1 | $1.43M | 1 | $1.43M | $0 |
| Adair Jason | Chief Business Officer | 0 | $0 | 13 | $233,001 | $-233,001 |
| Moomaw Scott | Chief Commercial Officer | 0 | $0 | 9 | $324,127 | $-324,127 |
| Saggar Rajeev | Chief Medical Officer | 0 | $0 | 9 | $410,845 | $-410,845 |
| Schundler Russell | General Counsel | 0 | $0 | 9 | $519,892 | $-519,892 |
| Kaseta Michael | CFO and COO | 0 | $0 | 9 | $781,329 | $-781,329 |
| JEFFS ROGER | Chief Executive Officer | 0 | $0 | 5 | $1.16M | $-1.16M |
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Over the last 12 months, insiders at Liquidia Corporation have bought $4.43M and sold $4.86M worth of Liquidia Corporation stock.
On average, over the past 5 years, insiders at Liquidia Corporation have bought $9.48M and sold $8.4M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Manning Paul B (director) — $3M. Caligan Partners LP (See Remarks) — $1.43M.
The last purchase of 337,078 shares for transaction amount of $3M was made by Manning Paul B (director) on 2024‑09‑12.
| 2025-06-04 | Sale | JEFFS ROGER | Chief Executive Officer | 30,610 0.0345% | $16.97 | $519,452 | -16.88% | |
| 2025-06-04 | Sale | Schundler Russell | General Counsel | 8,460 0.0095% | $16.97 | $143,566 | -16.88% | |
| 2025-06-04 | Sale | Kaseta Michael | CFO and COO | 14,777 0.0167% | $16.97 | $250,766 | -16.88% | |
| 2025-06-04 | Sale | Saggar Rajeev | Chief Medical Officer | 7,597 0.0086% | $16.97 | $128,921 | -16.88% | |
| 2025-06-04 | Sale | Moomaw Scott | Chief Commercial Officer | 6,656 0.0075% | $16.97 | $112,952 | -16.88% | |
| 2025-06-04 | Sale | Adair Jason | Chief Business Officer | 3,597 0.0041% | $16.97 | $61,041 | -16.88% | |
| 2025-06-02 | Sale | Schundler Russell | General Counsel | 923 0.0011% | $16.74 | $15,451 | -14.30% | |
| 2025-06-02 | Sale | Kaseta Michael | CFO and COO | 859 0.001% | $16.74 | $14,380 | -14.30% | |
| 2025-06-02 | Sale | Moomaw Scott | Chief Commercial Officer | 581 0.0007% | $16.74 | $9,726 | -14.30% | |
| 2025-06-02 | Sale | Adair Jason | Chief Business Officer | 451 0.0005% | $16.74 | $7,550 | -14.30% | |
| 2025-04-28 | Sale | Adair Jason | Chief Business Officer | 455 0.0005% | $14.24 | $6,479 | +10.26% | |
| 2025-04-21 | Sale | Saggar Rajeev | Chief Medical Officer | 2,450 0.0032% | $13.67 | $33,492 | +16.93% | |
| 2025-04-15 | Sale | Moomaw Scott | Chief Commercial Officer | 3,406 0.0044% | $13.57 | $46,219 | +11.60% | |
| 2025-04-14 | Sale | JEFFS ROGER | Chief Executive Officer | 14,130 0.0182% | $13.57 | $191,744 | +8.35% | |
| 2025-04-14 | Sale | Schundler Russell | General Counsel | 5,964 0.0077% | $13.57 | $80,931 | +8.35% | |
| 2025-04-14 | Sale | Kaseta Michael | CFO and COO | 8,283 0.0107% | $13.57 | $112,400 | +8.35% | |
| 2025-04-14 | Sale | Saggar Rajeev | Chief Medical Officer | 3,714 0.0048% | $13.57 | $50,399 | +8.35% | |
| 2025-04-14 | Sale | Adair Jason | Chief Business Officer | 1,856 0.0024% | $13.57 | $25,186 | +8.35% | |
| 2025-03-03 | Sale | Schundler Russell | General Counsel | 930 0.0012% | $15.45 | $14,369 | -0.64% | |
| 2025-03-03 | Sale | Kaseta Michael | CFO and COO | 874 0.0011% | $15.45 | $13,503 | -0.64% |
| Caligan Partners LP | See Remarks | 6994997 8.1828% | $95.41M | 2 | 1 | +67.76% |
| JEFFS ROGER | Chief Executive Officer | 1044979 1.2224% | $14.25M | 5 | 7 | +41.46% |
| Manning Paul B | director | 816311 0.9549% | $11.13M | 4 | 0 | +33.51% |
| Schundler Russell | General Counsel | 582054 0.6809% | $7.94M | 2 | 12 | +38.84% |
| Kaseta Michael | CFO and COO | 412164 0.4822% | $5.62M | 2 | 12 | +33.43% |
| Saggar Rajeev | Chief Medical Officer | 273209 0.3196% | $3.73M | 0 | 13 | |
| Moomaw Scott | Chief Commercial Officer | 224921 0.2631% | $3.07M | 1 | 17 | +17.85% |
| Adair Jason | Chief Business Officer | 193735 0.2266% | $2.64M | 0 | 21 | |
| JOHNSON DAVID EDWARD | 10643627 12.4509% | $145.18M | 4 | 0 | +22.98% | |
| Canaan VIII LP | 10 percent owner | 2917169 3.4125% | $39.79M | 2 | 0 | +22.07% |
| Eshelman Ventures, LLC | 10 percent owner | 2601210 3.0429% | $35.48M | 7 | 23 | <0.0001% |
| Bloch Stephen M | director | 2563303 2.9986% | $34.96M | 1 | 0 | +38.27% |
| BARRIS PETER J | 10 percent owner | 2484870 2.9068% | $33.89M | 1 | 0 | +38.27% |
| BARRETT M JAMES | 10 percent owner | 2484870 2.9068% | $33.89M | 1 | 0 | +38.27% |
| KERINS PATRICK J | 10 percent owner | 2484870 2.9068% | $33.89M | 1 | 0 | +38.27% |
| SANDELL SCOTT D | 10 percent owner | 2484870 2.9068% | $33.89M | 1 | 0 | +38.27% |
| BASKETT FOREST | 10 percent owner | 2484870 2.9068% | $33.89M | 1 | 0 | +38.27% |
| New Enterprise Associates 12, Limited Partnership | 10 percent owner | 2484870 2.9068% | $33.89M | 1 | 0 | +38.27% |
| GLAXOSMITHKLINE PLC | Former 10% holder | 624422 0.7305% | $8.52M | 1 | 0 | +38.27% |
| Alexandria Venture Investments, LLC | 10 percent owner | 396172 0.4634% | $5.4M | 1 | 0 | +38.27% |
| Lippe Robert A | Chief Operations Officer | 193788 0.2267% | $2.64M | 2 | 4 | +47.2% |
| GORDON KEVIN K | President and CFO | 162265 0.1898% | $2.21M | 0 | 2 | |
| Albury Timothy | SVP, Chief Accounting Officer | 38963 0.0456% | $531,455.32 | 0 | 3 | |
| Kirsch Arthur S | director | 32000 0.0374% | $436,480.00 | 4 | 0 | <0.0001% |
| Maynor Benjamin | SVP, Research and Development | 4168 0.0049% | $56,851.52 | 0 | 1 |
$8,217,280 | 112 | 46.33% | $1.02B | |
$831,902,292 | 108 | 9.34% | $1.16B | |
$54,590,806 | 65 | 21.84% | $1.33B | |
$11,583,737 | 45 | 49.75% | $1.28B | |
Liquidia Corporation (LQDA) | $100,002,191 | 42 | 21.48% | $1.17B |
$530,111,731 | 35 | 8.69% | $1.35B | |
$148,770,544 | 34 | 80.63% | $1.33B | |
$309,951,506 | 30 | 32.56% | $1.46B | |
$1,295,059 | 29 | 102.78% | $1.38B | |
$149,456,352 | 27 | -8.77% | $1.04B | |
$54,828,550 | 26 | -13.88% | $934.98M | |
$1,272,896 | 16 | 24.56% | $1.07B | |
$152,858,569 | 14 | -4.66% | $991.27M | |
$43,198,628 | 12 | -0.10% | $1.22B | |
$107,703,099 | 7 | 29.71% | $1.06B | |
$1,229,547 | 7 | 11.98% | $987.22M | |
$107,098,946 | 7 | 1.61% | $1.34B | |
$91,325,021 | 6 | 1.83% | $1.23B | |
$46,235,722 | 6 | -31.77% | $994.4M |
| Increased Positions | 94 | +53.11% | 9M | +17.81% |
| Decreased Positions | 74 | -41.81% | 6M | -11.2% |
| New Positions | 29 | New | 3M | New |
| Sold Out Positions | 25 | Sold Out | 677,581 | Sold Out |
| Total Postitions | 197 | +11.3% | 55M | +6.61% |
| Caligan Partners Lp | $128,517.00 | 9.55% | 8.12M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $74,907.00 | 5.57% | 4.73M | +70,397 | +1.51% | 2025-03-31 |
| Vanguard Group Inc | $56,312.00 | 4.18% | 3.56M | +115,367 | +3.35% | 2024-12-31 |
| Farallon Capital Management Llc | $52,096.00 | 3.87% | 3.29M | 0 | 0% | 2024-12-31 |
| Findell Capital Management Llc | $48,756.00 | 3.62% | 3.08M | -113,539 | -3.56% | 2024-12-31 |
| Kynam Capital Management, Lp | $35,876.00 | 2.67% | 2.27M | 0 | 0% | 2024-12-31 |
| Whitefort Capital Management, Lp | $31,458.00 | 2.34% | 1.99M | +285,220 | +16.76% | 2024-12-31 |
| Patient Square Capital Lp | $29,450.00 | 2.19% | 1.86M | -5M | -74.1% | 2024-12-31 |
| State Street Corp | $28,680.00 | 2.13% | 1.81M | -363,625 | -16.71% | 2024-12-31 |
| Vestal Point Capital, Lp | $27,861.00 | 2.07% | 1.76M | +260,000 | +17.33% | 2024-12-31 |